Highest-scoring questions on the site.
The particulars: 96.4% · chromatogram. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
Conditions: GL Biochem · ecnoglutide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would like…
For reference: fibrillation · semaglutide · 4 °C. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review…
What I am working with: GGPeps · survodutide. An unexpected observation, and I would like a differential rather than reassurance. The conditions were within what I…
Numbers first: 12 mg · retatrutide. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would still…
Concretely: FLOW · semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…
What I have: 8 mg · 4 mg/mL. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary; the method is what I am…
Numbers first: 4 °C · orforglipron. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists and…
What I have: mazdutide · 15 mg. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary; the method is what I…
The particulars: date of analysis · TFC. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping rules,…
The specifics, since they change the answer: 4 mg · 1 mL · phosphate-buffered diluent · orforglipron. I would like to define my thresholds before I have a result, for…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I can parse the result. I am less sure what it licenses me to conclude. I have…
Numbers first: 3.33 mg/mL · orforglipron. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a defensible…
What I am working with: Xi’an · Poland. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
What I have: 15 mg · sixteen weeks · reflux. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…
Numbers first: tirzepatide · SURMOUNT-2. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would…
For reference: 5 mg · ecnoglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement than on…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I keep seeing this stated as a fact with no explanation attached,…
The case in front of me: early satiety · two · survodutide. This is a procedural question rather than a theoretical one, and I would like the procedure rather than…
Conditions: potassium · semaglutide. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles that come…
What I have: SURMOUNT-4 · early satiety. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I have: a GLP-1 receptor agonist · purity figure. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
Details up front: a GLP-1 receptor agonist · 2–8 °C. I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has…
What I am working with: GL Biochem · an endotoxin test. I would like the arithmetic checked rather than the conclusion asserted. I have deliberately not used an…